Firdos Ahmad

List of Publications by Year in Descending Order

44 papers	841 citations	14 h-index	28 g-index
61 ext. papers	1,100 ext. citations	7.8 avg, IF	4.07 L-index

#	Paper	IF	Citations
44	SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19.. *International Journal of Laboratory Hematology*, **2022**,	2.5	3
43	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview.. *Clinical and Experimental Medicine*, **2022**, 1	4.9	0
42	Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19.. *Experimental Biology and Medicine*, **2022**, 15353702221091990	3.7	1
41	Abstract P357: Induction Of Soluble P-selectin And CD40 Ligand And, FXIII Deficiency Promote Aberrant Coagulation And Thromboembolism In Severe COVID-19. *Circulation Research*, **2021**, 129,	15.7	2
40	Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. *Cytokine and Growth Factor Reviews*, **2021**,	17.9	7
39	Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165609	6.9	4
38	Emerging roles of GSK-3 in pathophysiology: Emphasis on cardio-metabolic disorders. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118616	4.9	14
37	Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings. *Blood Reviews*, **2019**, 37, 100583	11.1	31
36	Cardiomyocyte-GSK-3 promotes mPTP opening and heart failure in mice with chronic pressure overload. *Journal of Molecular and Cellular Cardiology*, **2019**, 130, 65-75	5.8	13
35	Characterization of VWF gene conversions causing von Willebrand disease. *British Journal of Haematology*, **2019**, 184, 817-825	4.5	3
34	Cardiomyocyte-specific deletion of GSK-3 leads to cardiac dysfunction in a diet induced obesity model. *International Journal of Cardiology*, **2018**, 259, 145-152	3.2	12
33	Chronic Neuregulin-1 Treatment Mitigates the Progression of Postmyocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis, and Key Oxidant-Producing Enzymes. *Journal of Cardiac Failure*, **2017**, 23, 887-899	3.3	11
32	Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. *Circulation Research*, **2016**, 118, 1208-22	15.7	55
31	Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy". *Circulation Research*, **2016**, 119, e29-e30	15.7	3
30	The GSK-3 family as therapeutic target for myocardial diseases. *Circulation Research*, **2015**, 116, 138-49	15.7	127
29	Germline de novo mutations and linkage markers vs. DNA sequencing for carrier detection in von Willebrand disease. *Haemophilia*, **2014**, 20, e311-7	3.3	1
28	Cardiomyocyte-specific deletion of Gsk3 mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. *Journal of the American College of Cardiology*, **2014**, 64, 696-706	15.1	42

27	Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart. *Circulation*, **2014**, 130, 419-30	16.7	111
26	Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. *Circulation Journal*, **2014**, 78, 1514-9	2.9	14
25	Characterisation of mutations and molecular studies of type 2 von Willebrand disease. *Thrombosis and Haemostasis*, **2013**, 109, 39-46	7	25
24	Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. *Thrombosis and Haemostasis*, **2013**, 109, 652-60	7	13
23	GSK-3β is a central regulator of age-related pathologies in mice. *Journal of Clinical Investigation*, **2013**, 123, 1821-32	15.9	108
22	Human genome-wide association and mouse knockout approaches identify platelet supervillin as an inhibitor of thrombus formation under shear stress. *Circulation*, **2012**, 125, 2762-71	16.7	21
21	Glycogen synthase kinase-3β limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death. *Circulation*, **2012**, 125, 65-75	16.7	48
20	Relative contributions of stromal interaction molecule 1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2077-86	15.4	36
19	Role of RFLP using TspRI for carrier detection in Glanzmann's thrombasthenia: a report on two families. *International Journal of Laboratory Hematology*, **2010**, 32, e158-62	2.5	3
18	Impact of thrombogenic mutations on clinical phenotypes of von Willebrand disease. *Clinical and Applied Thrombosis/Hemostasis*, **2010**, 16, 281-7	3.3	5
17	Coinheritance of severe von Willebrand disease with Glanzmann thrombasthenia. *Clinical and Applied Thrombosis/Hemostasis*, **2010**, 16, 529-32	3.3	2
16	STIM1 Deficiency Results In Impaired Platelet Procoagulant Activity and Protection From Arterial Thrombosis. *Blood*, **2010**, 116, 485-485	2.2	
15	Critical Role of CalDAG-GEFI In FCRIIa-Dependent Platelet Activation and Thrombosis. *Blood*, **2010**, 116, 3196-3196	2.2	
14	Impact of 789Ala/Ala genotype on quantitative type of von Willebrand disease. *Annals of Hematology*, **2009**, 88, 479-83	3	8
13	Acquired Glanzmann's thrombasthenia associated with Hairy cell leukaemia. *European Journal of Clinical Investigation*, **2009**, 39, 1110-1	4.6	4
12	Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1878-85	15.4	41
11	Modulation of clinical phenotype of Glanzmann's thrombasthenia by thrombogenic mutations. *Clinica Chimica Acta*, **2009**, 403, 156-8	6.2	10
10	Glanzmann's thrombasthenia in North Indians: sub classification and carrier detection by flow cytometry. *Platelets*, **2009**, 20, 12-5	3.6	10

9	Inherited platelet function disorders versus other inherited bleeding disorders: an Indian overview. *Thrombosis Research*, **2008**, 121, 835-41	8.2	20
8	Carrier detection in Glanzmann thrombasthenia: comparison of flow cytometry and Western blot with respect to DNA mutation. *American Journal of Clinical Pathology*, **2008**, 130, 93-8	1.9	12
7	Glanzmann Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). *Blood*, **2008**, 112, 1236-1236	2.2	
6	Gene tracking in a family of novel identical twins affected by severe type-III von Willebrand Disease (vWD). *Thrombosis Research*, **2007**, 120, 459-62	8.2	1
5	Mutation Screening of GPIIb and GPIIIa Exons by Conformation Sensitive Gel Electrophoresis.. *Blood* , **2007**, 110, 3218-3218	2.2	
4	Use of CSGE, TspRI- RFLP and Western Blot in Carrier Detection in an Indian Family with Type I Glanzmann Thrombasthenia.. *Blood*, **2006**, 108, 3975-3975	2.2	1
3	Evidence for non-HFE linked hemochromatosis in Asian Indians. *Indian Journal of Medical Sciences*, **2006**, 60, 491-5		10
2	Functional characterization of antibodies against heparin-platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers. *Blood Coagulation and Fibrinolysis*, **2005**, 16, 487-90	1	3
1	Induction of soluble platelet activation markers and FXIII deficiency promote COVID-19 severity		2